A new neurotoxin called Jeuveau was approved by the FDA on February 1 to treat frown lines. The marketer of Jeuveau, Evolus, is the first business to join the fastest-growing area of the medical aesthetics market in almost ten years.
The new wrinkle therapy from Evolus is anticipated to be a major competitor to Botox from Allergan.
There is a new wrinkle remedy available.
Less than a year after the California-based company got marketing authority to advertise its wrinkle treatment for frown lines, Jeuveau received FDA approval.
In addition to global research involving over 2,100 patients with glabellar lines, sometimes referred to as “frown lines” between the brows, the Botox-like treatment underwent two Phase III U.S. studies. Researchers now think Jeuveau is a compelling and cutting-edge choice for the aesthetic treatment of glabellar lines because product studies showed promising results.
Customers may anticipate Jeuveau to be offered across the country in the spring of 2019. The business claims it would price the procedure between 20% and 25% less expensively than Allergan’s Botox, which brought in $3.5 billion in revenue last year.
A new wrinkle treatment for frown lines gives medical professionals and nurses who want to become certified in Botox the opportunity to broaden their service offerings and give their clients a less expensive Botox substitute.
